Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

Table 4 Probability of pharmacodynamic target attainment

		*C. albicans*	*C. glabrata*	*C. krusei*	*C. parapsilosis*	*C. tropicalis*	*A. fumigatus*	*A. niger*	*A. terreus*
Pfizer
4 mg/kg q12h	fAUC/MIC >25	99.9	86.3	97.9	99.5	99.6	97.1
	fAUC/MIC >35	99.8	81.6	94.8	99.2	99.3	92.8
6 mg/kg q12h	fAUC/MIC >25	99.9	90.0	99.1	99.7	99.8	99.2
	fAUC/MIC >35	99.8	86.8	98.3	99.6	99.6	97.9
EUCAST
4 mg/kg q12h	fAUC/MIC >25	99.2					90.3	77.2	60.5
4 mg/kg q12h	fAUC/MIC >35	99.1					80.3	61.9	41.6
6 mg/kg q12h	fAUC/MIC >25	99.4					96.3	91.7	81.4
6 mg/kg q12h	fAUC/MIC >35	99.2					92.1	80.3	65.4
8 mg/kg q12h	fAUC/MIC >25							96.4	89.5
8 mg/kg q12h	fAUC/MIC >35							90.6	79.0
10 mg/kg q12h	fAUC/MIC >25							98.6	94.1
10 mg/kg q12h	fAUC/MIC >35							95.4	86.1
12 mg/kg q12h	fAUC/MIC >25								96.6
12 mg/kg q12h	fAUC/MIC >35								90.6
CLSI
4 mg/kg q12h	fAUC/MIC >25	99.1	89.1	94.1	99.6	98.0
4 mg/kg q12h	fAUC/MIC >35	99.0	86.0	88.1	99.3	97.7
6 mg/kg q12h	fAUC/MIC >25	99.6	92.9	98.0	99.7	98.0
6 mg/kg q12h	fAUC/MIC >35	99.5	89.9	95.3	99.6	97.9

Data reported as % of patients obtaining target fAUC/MIC ratio at the prescribed dose. Data not available for every organism within all databases. fAUC0-12, free area under the concentration-time curve from 0 to 12 hours; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; CLSI, Clinical and Laboratory Standards Institute.

ISSN: 1364-8535